J3372 — Injection, vancomycin hcl (xellia), not therapeutically equivalent to j3370, 500 mg
J3372 is a HCPCS Level II code for injection, vancomycin hcl (xellia), not therapeutically equivalent to j3370, 500 mg. It belongs to the Drugs Administered Other Than Oral Method section. It was terminated on June 30, 2025 and is not valid on new claims.
This code has been terminated
CMS terminated J3372 on June 30, 2025. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Special coverage instructions apply
There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for J3372
- Long descriptor
- Injection, vancomycin hcl (xellia), not therapeutically equivalent to j3370, 500 mg
- Short descriptor
- Inj, vancomycin hcl (xellia)
- Added
- January 1, 2023
- Terminated
- June 30, 2025
- BETOS
- O1E
- Pricing indicator
- 51 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Drugs.
Codes adjacent to J3372
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If J3372 is not quite right, the correct code is very often within a few positions of it.
- J3355Injection, urofollitropin, 75 iuterminated
- J3357Ustekinumab, for subcutaneous injection, 1 mg
- J3358Ustekinumab, for intravenous injection, 1 mg
- J3360Injection, diazepam, up to 5 mg
- J3364Injection, urokinase, 5000 iu vialterminated
- J3365Injection, iv, urokinase, 250,000 i.u. vialterminated
- J3370Injection, vancomycin hcl, 500 mgterminated
- J3371Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mgterminated
- J3373Injection, vancomycin hydrochloride, 10 mg
- J3374Injection, vancomycin hydrochloride (mylan) not therapeutically equivalent to j3373, 10 mg
- J3375Injection, vancomycin hydrochloride (tyzavan), not therapeutically equivalent to j3373, 10 mg
- J3376Injection, vancomycin hcl (hikma), not therapeutically equivalent to j3373, 10 mg
- J3379Injection, valproate sodium, 5 mg
- J3380Injection, vedolizumab, intravenous, 1 mg
- J3385Injection, velaglucerase alfa, 100 units
- J3386Injection, etuvetidigene autotemcel, per treatment
Questions about J3372
What is HCPCS code J3372?
J3372 is a HCPCS Level II code for injection, vancomycin hcl (xellia), not therapeutically equivalent to j3370, 500 mg. It sits in the Drugs Administered Other Than Oral Method section.
Does Medicare cover J3372?
The CMS HCPCS file marks J3372 as "Special coverage instructions apply". There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
Is J3372 still valid?
No. J3372 was terminated on June 30, 2025 and should not be used on new claims.